A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Vyv Announces Groundbreaking Inactivation And Killing Of Viruses With Its UV-free Antimicrobial Light Technology

Vyv, a female-founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.

Numerous studies have proven the effectiveness of Vyv’s visible light against bacteria, mold, fungi, and yeast.

This recent study has confirmed, through an independent third-party lab, Vyv’s antimicrobial LED products are also effective against non-enveloped viruses, which are the most difficult class of virus to kill*.

“The implications of this are vast because, unlike harmful UV-C light, Vyv’s patented technology can be used continuously and without restriction 24/7 around people, animals, and plants. The recent findings of enhanced efficacy against viruses greatly expand the antimicrobial impact delivered to spaces currently protected with Vyv technology, as well as in new spaces,” said Vyv CEO and co-founder Colleen Costello. “With our overhead LED products, Vyv is already lighting offices, schools and school buses, athletic centers, factories and hospitals. We’re also embedding the same technology in many challenging spaces, including behind elevator buttons, inside consumer products such as humidifiers and bathroom fans, and in airplanes, trains, and public buses.”

Additionally, a recent separate third-party study completed by the Icahn School of Medicine at Mount Sinai also demonstrated efficacy results using ranges of light in the 400-420nm range on inactivating enveloped viruses. With Vyv’s commitment to ongoing research and development advancements of a myriad of new products for healthier spaces, the company will continue to expand its virus testing in the coming months.

The company has announced several high-profile business partnerships and investments with industry front-runners over the past six months. While the COVID-19 global pandemic continues to impact day-to-day life around the world, Vyv has joined forces and expanded development projects with Middleby Corporation, Citi, NJ Transit, Delta Air Lines, Broan-NuTone, Dorel Juvenile and Brilli, among several other well-respected brands. Most recently, Vyv announced a partnership with the Healthcare Association of New York State (HANYS), which is working to advance new approaches to infection control and prevention by dosing interior environments continuously with antimicrobial light to stop and kill* viruses, bacteria, fungi, mold and other organisms.

“Our partners have long understood the threats to global health and wellness. Many of these companies began engineering new solutions with Vyv’s antimicrobial light long before the current pandemic. We’ve been on a path together to bring a new class of continuous microbial protection to address the world’s ever-evolving microbial challenges,” said Costello.

SourceVyv
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy